BMI View: Hungary's pharmaceutical market represents a moderate but reliable commercial prospect within Central and Eastern Europe. The government plays a key role in the provision of medical services as demonstrated by its recent ban on parallel exports of medicines and the decentralization of primary care. The private sector is expected to become more involved over the medium term. BMI anticipates the 10-year compound annual growth rate for the € 2.48bn market at 3.9%.
Data from the HSCO reveals that pharmaceutical expenditure in Hungary is broadly split between compulsory government schemes and household out-of pocket payments, with the remainder coming from voluntary healthcare payment schemes. Due to fiscal constraints, the state has been seeking to control its spending though strict budgeting and containment measures such as setting price mark-ups for generic drugs.
Pharmaceutical market of Hungary has a small, but reliable commercial prospect in Central and Eastern Europe. The government plays a key role in provision of medical services, which testifies to its recent prohibition on parallel export of medicines, and decentralization of primary health care.
Pharma services companies in Hungary work with such regulatory bodies as the Hungarian central statistical office, which keeps all statistical data in in the area of health care.
This regulatory affairs authority obtains data within the frameworks of the national statistical data collection program. This body fixes number of patients with various diseases, collates demographic statistics, number of accidents, measures state of health on gender and age, collects data on invalidization and other.
In Hungary pharmaceutical authorities regulate the system of obligatory national health insurance. There exist a "positive" list of the medicines, which are subject to be reimbursed, and the other list includes categories of medicines that are not compensated by the state. The amount of compensation of cost of medicines depends on disease severity.
The Hungarian central statistical office of Hungary specifies categories of medicines which are reimbursed: those are drugs that are not compensated (0%); reimbursement is valid for any prescription and indication (25; 55; 80% of cost); compensation taking into account symptoms (50; 70; 90; 100%).
Regulatory services and regulatory affairs companies help pharmaceutical companies to register pharma products in Eastern European markets.